Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate

International Journal of Impotence Research

Volumn 14, Issue 1, 2002, Pages 38-43

  Israilov, S ^a   Niv, E ^b   Livne, P M ^a   Shmueli, J ^a   Engelstein, D ^a   Segenreich, E ^a   Baniel, J ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b MEIR MEDICAL CENTER   (Israel)

Author keywords

Cardiovascular disease; Erectile dysfunction; Intracavernous therapy; Progressive treatment program; Sildenafil citrate

Indexed keywords

ATROPINE; PAPAVERINE; PHENTOLAMINE; PROSTAGLANDIN E1; SILDENAFIL; VASOACTIVE AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PENIS ERECTION; PRIORITY JOURNAL; TACHYCARDIA; TREATMENT FAILURE; TREATMENT OUTCOME; VERTIGO; VISUAL DISORDER;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ALPROSTADIL; ATROPINE; CARDIOVASCULAR DISEASES; COITUS; DRUG COMBINATIONS; FOLLOW-UP STUDIES; HUMANS; IMPOTENCE; INJECTIONS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PAPAVERINE; PENIS; PHENTOLAMINE; PIPERAZINES; RETREATMENT; TREATMENT FAILURE; VASODILATOR AGENTS;

EID: 0036189223     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3900812     Document Type: Article

References (27)

1. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease
2. Oral sildenafil in the treatment of erectile dysfunction
3. Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction
4. A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction
5. Erectile dysfunction and sildenafil citrate and cardiologists
6. Overall cardiovascular profile of sildenafil citrate
7. Hemodynamic effects of sildenafil in men with severe coronary artery disease
8. Initial results utilizing combination therapy for patients with a suboptimal response to either alprostadil or sildenafil monotherapy
9. Side-effect profile of sildenafil citrate (Viagra) in clinical practice
10. Use of sildenafil (Viagra) in patients with cardiovascular disease
11. The Israel Heart Society Expert Consensus document: The cardiac patient and sexual activity in the era of sildenafil (Viagra)
12. The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction
13. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function
14. Treatment of intracorporeal injection nonresponders with sildenafil alone or in combination with triple agent intracorporeal injection therapy
15. Intracavernous alprostadil alfadex (Edem/Viridal) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra)
16. Sildenafil versus intracavernous injection therapy: Efficacy and preference in patients on intracavernous injection for more than 1 y
17. Intracavernous self-injection with phentolamine and papaverine for the treatment of impotence
18. 1 in erectile dysfunction
19. Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence
20. 1 in combination with papaverine-enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E
21. Intracavernosal therapy for erectile failure - Impact of treatment and reasons for dropout and dissatisfaction
22. 1
23. Four-drug intracavernous therapy for impotence due to corporeal veno-occlusive dysfunction
24. Atropine role in the pharmacological erection test: Study of 228 patients
25. Return of spontaneous erection during long-term cavernosal alprostadil (Caverject) treatment
26. Nocturnal penile tumescence activity unchanged after long-term intracavernous injection therapy